Ocrevus® is the official global commercial brand name, and Luokeshi is its Chinese brand name developed by Roche. It is a humanized anti‑CD20 monoclonal antibody. It selectively depletes CD20‑positive B‑lymphocytes, inhibits pathological autoimmune inflammatory responses in the central nervous system, and slows disease progression of multiple sclerosis.
Main Indications
Treatment of adult relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing‑remitting multiple sclerosis and active secondary progressive multiple sclerosis;
Treatment of adult primary progressive multiple sclerosis (PPMS).
Clinical Research
Global multicenter phase III pivotal trials demonstrated that ocrelizumab significantly reduces annualized relapse rate, slows disability progression and lowers brain lesion activity in RMS patients;
ORATORIO trial confirmed that ocrelizumab delays the progression of physical disability in PPMS adult patients;
Long‑term follow‑up data showed sustained therapeutic benefits over multiple years;
Clinical data including Asian subjects showed consistent efficacy and safety outcomes compared with global populations.
Common Side Effects
Infusion‑related reactions: pruritus, rash, throat irritation, hypotension, dyspnea (severe infusion reactions occur rarely);
Increased infection risk: upper respiratory tract infection, urinary tract infection, herpes virus infection, progressive multifocal leukoencephalopathy (very rare but severe);
Common mild adverse reactions: headache, fatigue, nausea, diarrhoea, back pain, arthralgia.
Approval Status in China
Original drug Ocrevus® (Ocrelizumab Injection) was officially approved for marketing in China in 2025, with the specification of 300mg(10mL)/vial. It has been included in China’s national medical insurance catalogue.
Buy Ocrevus (Ocrelizumab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
